Rezolute, Inc. (NASDAQ: RZLT) presented expanded analyses from its Phase 3 sunRIZE study at the Pediatric Endocrine Society (PES) 2026 Annual Meeting on May 1, 2026. The presentation, led by Dr. Diva D. De León‑Crutchlow, highlighted additional continuous glucose monitoring (CGM) outcomes that demonstrate significant and consistent glycemic improvements in ersodetug treatment arms versus placebo across multiple pre‑specified and post‑hoc endpoints.
The CGM data showed clinically relevant reductions in time spent in hypoglycemia and increases in time in target glucose range, with improvements that were consistent across all key metrics. These findings reinforce the drug’s target‑engagement profile and suggest that ersodetug can deliver meaningful therapeutic benefit even though the primary endpoint of the sunRIZE study was not met.
All 59 study completers entered an open‑label extension (OLE) phase, and 57 participants continued regular visits and received ersodetug. Preliminary OLE observations indicate sustained glycemic benefit, a notable reduction in background standard‑of‑care therapies, and a shift toward ersodetug monotherapy for several patients.
The presentation follows a March 17, 2026 FDA meeting in which the agency acknowledged challenges with the primary endpoint and requested submission of the full study data set. Rezolute’s expanded data presentation is intended to inform the ongoing regulatory dialogue and to support a potential accelerated approval pathway.
Chief Medical Officer Brian Roberts said, “We are pleased to highlight that deeper analyses of the sunRIZE outcomes and ongoing observations from the extension phase of the study consistently indicate evidence of target engagement, drug activity, and the potential for meaningful therapeutic benefit from ersodetug.” He added, “These results underscore our confidence in the potential of ersodetug to transform the HI treatment landscape and embolden our mission to achieve alignment with FDA on an acceptable path.”
Rezolute is a clinical‑stage company with no product revenue. As of June 30, 2025, it held $167.9 million in cash, cash equivalents, and investments, providing a strong runway for continued development. The company’s next earnings report is scheduled for May 13, 2026.
Congenital hyperinsulinism (HI) is a rare disease that causes dangerously low blood sugar levels. Current therapies—diazoxide, octreotide, and surgery—have limited efficacy and significant side‑effect profiles. Ersodetug, a fully human monoclonal antibody that allosterically binds the insulin receptor, offers a novel mechanism that could address the unmet need for a safe, effective, and broadly applicable treatment.
The expanded sunRIZE data, combined with the OLE findings and regulatory engagement, position Rezolute to advance ersodetug toward potential approval and to capture a meaningful share of the HI market, which is expected to grow as genetic testing and precision medicine expand.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.